Kamil Aleksander Kunecki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kamil Aleksander Kunecki has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander Urbaś
Murcki Hospital in Katowice, Poland
1 shared publication - Edyta Dziadkowiak
Clinical Department of Neurology, University Centre of Neurology and Neurosurgery, Faculty of Medicine, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland
1 shared publication - Emil Plichta
Medical University of Silesia, Katowice, Poland
1 shared publication - Jan Wandzel
Medical University of Silesia, Katowice, Poland
1 shared publication - Katarzyna Wilk
Medical University of Silesia, Katowice, Poland
1 shared publication - Małgorzata Wandzel
Medical University of Silesia
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 74005
Supportive organ management in acute right ventricular failure secondary to pulmonary embolism: a narrative review
Background. Pulmonary embolism (PE) is among the most common cardiovascular syndromes and a leading cause of acute right ventricular failure (ARVF), which drives haemodynamic and respiratory deterioration and high mortality. While causal treatment removes the thrombus, supportive organ management keeps patients alive until it takes effect, yet clear algorithms are lacking. Aim. To review the pathophysiology of ARVF in PE and available supportive (haemodynamic, oxygenation, ventilation) strategies, appraising their efficacy, safety and evidence quality. Material and methods. Narrative review of PubMed and Google Scholar (2016–2026, with justified exceptions), using Boolean combinations of terms on right ventricular failure, PE and organ support. 36 studies were narratively synthesised, each assessed for design, sample size and methodology. Results. ARVF in PE stems from RV pressure overload uncoupling contractility from afterload, causing RV dilatation, septal shift, LV underfilling and ischaemia. Supportive care targets preload, afterload and contractility. High-flow oxygen therapy appears superior to low-flow and possibly comparable to non-invasive ventilation; positive-pressure ventilation risks haemodynamic harm. Fluids require cautious titration guided by CVP and VExUS. Noradrenaline and dobutamine are preferred; levosimendan and milrinone reduce pulmonary vascular resistance but risk hypotension. Inhaled vasodilators (notably nitric oxide) and oxygen show promise but unproven benefit. Mechanical circulatory support (mainly VA-ECMO) is a bridging option, best combined with embolectomy. Conclusions. Management of ARVF in PE demands combined causal and supportive treatment, but much supportive care rests on extrapolated or low-quality evidence; PE-specific studies are needed.
- 25 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 74005
Open AccessSupportive organ management in acute right ventricular failure secondary to pulmonary embolism: a narrative review
Background. Pulmonary embolism (PE) is among the most common cardiovascular syndromes and a leading cause of acute right ventricular failure (ARVF), which drives haemodynamic and respiratory deterioration and high mortality. While causal treatment removes the thrombus, supportive organ management keeps patients alive until it takes effect, yet clear algorithms are lacking. Aim. To review the pathophysiology of ARVF in PE and available supportive (haemodynamic, oxygenation, ventilation) strategies, appraising their efficacy, safety and evidence quality. Material and methods. Narrative review of PubMed and Google Scholar (2016–2026, with justified exceptions), using Boolean combinations of terms on right ventricular failure, PE and organ support. 36 studies were narratively synthesised, each assessed for design, sample size and methodology. Results. ARVF in PE stems from RV pressure overload uncoupling contractility from afterload, causing RV dilatation, septal shift, LV underfilling and ischaemia. Supportive care targets preload, afterload and contractility. High-flow oxygen therapy appears superior to low-flow and possibly comparable to non-invasive ventilation; positive-pressure ventilation risks haemodynamic harm. Fluids require cautious titration guided by CVP and VExUS. Noradrenaline and dobutamine are preferred; levosimendan and milrinone reduce pulmonary vascular resistance but risk hypotension. Inhaled vasodilators (notably nitric oxide) and oxygen show promise but unproven benefit. Mechanical circulatory support (mainly VA-ECMO) is a bridging option, best combined with embolectomy. Conclusions. Management of ARVF in PE demands combined causal and supportive treatment, but much supportive care rests on extrapolated or low-quality evidence; PE-specific studies are needed.
- Open Access
- 27 April 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (12)
Autoimmune mechanisms in drug-resistant focal epilepsy: Pathophysiology, biomarkers, and therapeutic implications
This review explores the role of autoimmune mechanisms in drug-resistant epilepsy (DRE), with emphasis on etiology, mechanisms of drug resistance, and potential immunomodulatory interventions. A structured review of clinical and experimental studies was conducted to assess current knowledge on the interplay between molecular mechanisms and immune responses in DRE. Particular attention was given to the involvement of the mTOR pathway, blood-brain barrier (BBB) dysfunction, astrocyte activation, and overexpression of efflux transporters, as well as the presence of neuronal autoantibodies such as N-methyl-D-aspartate receptor (NMDAR) and GluR3. The available evidence suggests that, although conventional pharmacologic approaches fail in a subset of patients, immunologic diagnostics and targeted therapies - including intravenous immunoglobulin, corticosteroids, rituximab, and plasmapheresis - may provide clinical benefit. Seizure reduction has been reported in selected patients; however, therapeutic response remains heterogeneous and is limited by small study populations. In conclusion, early identification of autoimmune mechanisms in DRE may help optimize treatment strategies, improve patient outcomes, and reduce the long-term clinical and societal burden of the disease.
- 27 April 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (12)
Open AccessAutoimmune mechanisms in drug-resistant focal epilepsy: Pathophysiology, biomarkers, and therapeutic implications
This review explores the role of autoimmune mechanisms in drug-resistant epilepsy (DRE), with emphasis on etiology, mechanisms of drug resistance, and potential immunomodulatory interventions. A structured review of clinical and experimental studies was conducted to assess current knowledge on the interplay between molecular mechanisms and immune responses in DRE. Particular attention was given to the involvement of the mTOR pathway, blood-brain barrier (BBB) dysfunction, astrocyte activation, and overexpression of efflux transporters, as well as the presence of neuronal autoantibodies such as N-methyl-D-aspartate receptor (NMDAR) and GluR3. The available evidence suggests that, although conventional pharmacologic approaches fail in a subset of patients, immunologic diagnostics and targeted therapies - including intravenous immunoglobulin, corticosteroids, rituximab, and plasmapheresis - may provide clinical benefit. Seizure reduction has been reported in selected patients; however, therapeutic response remains heterogeneous and is limited by small study populations. In conclusion, early identification of autoimmune mechanisms in DRE may help optimize treatment strategies, improve patient outcomes, and reduce the long-term clinical and societal burden of the disease.